NCT03970226View on ClinicalTrials.gov

Tocilizumab in Children With ACP

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 16, 2019

Primary Completion Date

May 26, 2024

Study Completion Date

December 31, 2025

Conditions
Adamantinomatous Craniopharyngioma
Interventions
DRUG

Tocilizumab

"Phase 0: One dose of tocilizumab prior to surgery~Feasibility phase: Tocilizumab administered every 2 weeks for up to 13 cycles (approximately 1 year)."

Trial Locations (1)

80045

Children's Hospital Colorado, Aurora

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

University of Colorado, Denver

OTHER